Generation of Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) Using Directed Molecular Evolution
互联网
- Abstract
- Table of Contents
- Materials
- Figures
- Literature Cited
Abstract
G protein?coupled receptors (GPCRs) and their signal transductions are important for both physiological and pathological processes in neuron systems. Neuronal GPCRs activated by synthetic ligands have been created by designed mutagenesis for studying their functions and signal pathways. However, these engineered GPCRs have problems, such as their high constitutive activity. To overcome this drawback, a new generation of receptors termed designer receptors exclusively activated by designer drugs (DREADDs), have been designed. DREADDs are exclusively activated by synthetic ligands, but are insensitive to their endogenous ligand and have no constitutive activity, which provides the ability to selectively modulate signal transduction of certain GPCRs in vitro and in vivo. This protocol provides detailed instructions for creating DREADDs using directed molecular evolution. The procedures to generate DREADDS include GPCR functional expression in yeast, mutant GPCR library generation, and high?throughput yeast screening. These methods are general and suitable for any GPCRs that can be functionally expressed in yeast. Curr. Protoc. Neurosci. 50:4.33.1?4.33.25. © 2010 by John Wiley & Sons, Inc.
Keywords: DREADD; RASSL; directed molecular evolution; synthetic biology; chemical biology
Table of Contents
- Introduction
- Strategic Planning
- Basic Protocol 1: Expression and Testing of the Function of the Target GPCR in Yeast
- Basic Protocol 2: Generating Yeast Mutant Libraries Expressing Randomly Mutated Receptors
- Basic Protocol 3: Yeast Mutant Library Screening and Liquid Yeast Growth Assays
- Basic Protocol 4: Determine the Mutation Site(s) and Confirm the Pharmacological Profile of Selected Candidates
- Reagents and Solutions
- Commentary
- Literature Cited
- Figures
- Tables
Materials
Basic Protocol 1: Expression and Testing of the Function of the Target GPCR in Yeast
Materials
Basic Protocol 2: Generating Yeast Mutant Libraries Expressing Randomly Mutated Receptors
Materials
Basic Protocol 3: Yeast Mutant Library Screening and Liquid Yeast Growth Assays
Materials
Basic Protocol 4: Determine the Mutation Site(s) and Confirm the Pharmacological Profile of Selected Candidates
Materials
|
Figures
-
Figure 4.33.1 An outline of experimental planning. Preliminary experiments that test whether the target GPCR can function in yeast cells (see ) are first performed, followed by screening compound selection (see ). Then, the mutant library is generated and screening cycles are done. View Image -
Figure 4.33.2 Liquid yeast growth assay for a small number of samples. See , steps 9 to 23, for detailed descriptions. View Image -
Figure 4.33.3 Yeast cells show different growth curves on different days (EC50 is not a fixed number for yeast). Cells expressing hCB1 receptor (N‐terminal truncated version) are utilized as an example in this figure. (A ) Growth curves after 2‐day incubation. The EC50 values with AEA and WIN55212‐2 are 837 nM and 5691 nM, respectively. (B ) Growth curves after 3‐day incubation. The EC50 values with AEA and WIN55212‐2 both decreased (223 nM and 676 nM, respectively) compared to that in A. View Image -
Figure 4.33.4 A diagram of the “gap repair” method. See for detailed description. View Image -
Figure 4.33.5 Liquid yeast growth assay designed for high‐throughput screening. See , steps 6 to 19, for detailed description. View Image -
Figure 4.33.6 An illustration of growth assay profiles of a potential mutant candidate for DREADD screening. (A ) The selected pharmacologically inert drug cannot activate the wild‐type receptor but can activate the mutant no. x . (B ) The endogenous ligand shows significantly decreased potency on activating the mutant no. x compared to the wild‐type receptor. View Image
Videos
Literature Cited
Literature Cited | |
Alexander, G.M., Rogan, S.C., Abbas, A.I., Armbruster, B.N., Pei, Y., Allen, J.A., Nonneman, R.J., Hartmann, J., Moy, S.S., Nicolelis, M.A., McNamara, J.O., and Roth, B.L. 2009. Remote control of neuronal activity in transgenic mice expressing evolved G protein‐coupled receptors. Neuron 63:27‐39. | |
Armbruster, B.N., Li, X., Pausch, M.H., Herlitze, S., and Roth, B.L. 2007. Evolving the lock to fit the key to create a family of G protein–coupled receptors potently activated by an inert ligand. Proc. Natl. Acad. Sci. U.S.A. 104:5163‐5168. | |
Beukers, M.W. and Ijzerman, A.P. 2005. Techniques: How to boost GPCR mutagenesis studies using yeast. Trends Pharmacol. Sci. 26:533‐539. | |
Bockaert, J. and Pin, J.P. 1999. Molecular tinkering of G protein–coupled receptors: An evolutionary success. Embo. J. 18:1723‐1729. | |
Chung, K.S., Won, M., Lee, J.J., Ahn, J., Hoe, K.L., Kim, D.U., Song, K.B., and Yoo, H.S. 2007. Yeast‐based screening to identify modulators of G‐protein signaling using uncontrolled cell division cycle by overexpression of Stm1. J. Biotechnol. 129:547‐554. | |
Conklin, B.R., Hsiao, E.C., Claeysen, S., Dumuis, A., Srinivasan, S., Forsayeth, J.R., Guettier, J.M., Chang, W.C., Pei, Y., McCarthy, K.D., Nissenson, R.A., Wess, J., Bockaert, J., and Roth, B.L. 2008. Engineering GPCR signaling pathways with RASSLs. Nat. Methods 5:673‐678. | |
Coward, P., Wada, H.G., Falk, M.S., Chan, S.D., Meng, F., Akil, H., and Conklin, B.R. 1998. Controlling signaling with a specifically designed Gi‐coupled receptor. Proc. Natl. Acad. Sci. U.S.A. 95:352‐357. | |
Dowell, S.J. and Brown, A.J. 2002. Yeast assays for G‐protein‐coupled receptors. Receptor Channel 8:343‐352. | |
Erlenbach, I., Kostenis, E., Schmidt, C., Hamdan, F.F., Pausch, M.H., and Wess, J. 2001. Functional expression of M(1), M(3) and M(5) muscarinic acetylcholine receptors in yeast. J. Neurochem. 77:1327‐1337. | |
Gether, U. 2000. Uncovering molecular mechanisms involved in activation of G protein–coupled receptors. Endocr. Rev. 21:90‐113. | |
Guettier, J.M., Gautam, D., Scarselli, M., de Azua, I.R., Li, J.H., Rosemond, E., Ma, X., Gonzalez, F.J., Armbruster, B.N., Lu, H., Roth, B.L., and Wess, J. 2009. A chemical‐genetic approach to study G protein regulation of beta cell function in vivo. Proc. Natl. Acad. Sci. U.S.A. 106:19197‐19202. | |
Hermans, E. 2003. Biochemical and pharmacological control of the multiplicity of coupling at G‐protein‐coupled receptors. Pharmacol. Ther. 99:25‐44. | |
Ishii, J., Tanaka, T., Matsumura, S., Tatematsu, K., Kuroda, S., Ogino, C., Fukuda, H., and Kondo, A. 2008. Yeast‐based fluorescence reporter assay of G protein‐coupled receptor signaling for flow cytometric screening: FAR1‐disruption recovers loss of episomal plasmid caused by signaling in yeast. J. Biochem. 143:667‐674. | |
Josefsson, L.G. 1999. Evidence for kinship between diverse G‐protein‐coupled receptors. Gene 239:333‐340. | |
Ladds, G. and Davey, J. 2004. Analysis of human GPCRs in fission yeast. Curr. Opin. Drug Discov. Devel. 7:683‐691. | |
Ladds, G., Goddard, A., and Davey, J. 2005. Functional analysis of heterologous GPCR signalling pathways in yeast. Trends Biotechnol. 23:367‐373. | |
Minic, J., Sautel, M., Salesse, R., and Pajot‐Augy, E. 2005. Yeast system as a screening tool for pharmacological assessment of G protein–coupled receptors. Curr. Med. Chem. 12:961‐969. | |
Mumberg, D., Muller, R., and Funk, M. 1995. Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. Gene 156:119‐122. | |
Pei, Y., Rogan, S.C., Yan, F., and Roth, B.L. 2008. Engineered GPCRs as tools to modulate signal transduction. Physiology 23:313‐321. | |
Scearce‐Levie, K., Coward, P., Redfern, C.H., and Conklin, B.R. 2001. Engineering receptors activated solely by synthetic ligands (RASSLs). Trends Pharmacol. Sci. 22:414‐420. |